Description: Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Home Page: www.cyxone.com
Adelgatan 21
Malmö,
221 22
Sweden
Phone:
46 7 08 88 21 72
Officers
| Name | Title |
|---|---|
| Mr. Carl-Magnus Hogerkorp | COO & Acting CEO |
| Mr. Ola Skanung | Chief Financial Officer |
| Ms. Erika Samuelsson | Chief Devel. Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9968 |
| Price-to-Sales TTM: | 5168.3467 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |